SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging following a preliminary business update where the company reported a record backlog exceeding $60 billion and projected gross margins nearly doubling to 15-17%, signaling stronger-than-expected profitability and continued demand for AI infrastructure. Community members are actively debating the sustainability of these margins and the potential for a short squeeze, given significant institutional short interest and conflicting reactions from analysts regarding the company's long-term transparency and management.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors rally around a surge in new defense contracts and strong volume, fueling optimism for a potential short squeeze. The community is actively discussing the company's autonomous drone technology, the high cost to borrow shares, and the expectation that upcoming earnings will validate a long-term growth thesis.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is seeing high volatility as investors weigh the platform's potential for AI data monetization against concerns regarding traffic sustainability and contract negotiations with major search engines. The community remains deeply divided, with many actively debating whether current pullbacks are tactical buying opportunities or signs of underlying platform instability heading into upcoming earnings.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is experiencing extreme volatility and massive, unusual trading volume as the community debates whether the heavy activity signals institutional accumulation or ongoing market manipulation. Investors are increasingly focused on the stock's significant short interest and strategic pivot toward agentic AI, with many monitoring for a potential breakout above key resistance levels that could trigger a squeeze.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending ahead of its quarterly earnings release as investors remain sharply divided over whether enterprise AI will drive long-term software demand or act as a disruptive threat. The community is actively debating the stock's recent volatility, with many traders looking for a potential bounce or "snapback" fueled by strong subscription growth and AI-focused institutional buybacks.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is currently in focus as investors await earnings, with market participants closely scrutinizing the company's capital expenditure on AI infrastructure and its ability to monetize these investments. Community discussion remains polarized, featuring debates on the potential impact of hyperscaler spending on semiconductor stocks, concerns over contract renegotiations with major publishers, and skepticism regarding the competitive edge of upcoming Gemini AI model releases.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund is trending as intensifying U.S.-Iran military strikes and mounting threats to critical shipping routes like the Strait of Hormuz and the Bab el-Mandeb Strait fuel investor anxiety over supply disruptions. The community is actively debating the geopolitical risks to energy markets, with many traders closely watching for signals of further escalation or diplomatic intervention that could lead to volatility.

GE Vernova, Inc. engages in the electric power industry. It operates through the following segments: Power, Wind, and Electrification. The Power segment offers design, manufacture, and servicing gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment manages wind generation technologies, including onshore and offshore wind turbines and blades. The Electrification segment refers to the grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The company was founded November 9, 2021 and is headquartered in Cambridge, MA.

GE Vernova Inc.

GE Vernova is trending as investors weigh a bottom-line earnings miss against strong order growth and an raised fiscal year outlook, with many viewing the pullback as a buying opportunity to gain exposure to the AI-driven power infrastructure cycle. The community remains focused on the company's massive order backlog and its strategic position as a critical provider of turbines and grid equipment for expanding data center energy requirements.

Aurora Innovation, Inc. engages in the design and development of automobile hardware, software, and provision of data services. It offers the Aurora Driver which allows a vehicle to drive itself. The company was founded by Christopher Urmson, Sterling Anderson and James Andrew Bagnell in 2017 and is headquartered in Pittsburgh, PA.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is trending as the community reacts to the launch of its second-generation driverless trucks and monitors management's execution on production milestones. Investors are closely debating the potential impact of strategic partnerships and future scaling, while some are actively navigating recent price volatility as a long-term entry point.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals is trending following positive Phase 3 topline results for its plozasiran program in patients with severe hypertriglyceridemia, which successfully met primary and secondary endpoints. The community is actively discussing the drug's best-in-class potential for acute pancreatitis risk reduction and the broader implications for Arrowhead's maturing RNAi platform.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026...

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsAmgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income...

Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption

Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption...

IBRX Stock Outlook After Q1 Results and a New FDA Review

ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.

ImmunityBio: Anktiva Explained and What Comes Next

IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.

AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.

Why Is IOVA Stock Falling Today?

Equity

During the first quarter, Iovance posted a 45% increase in revenue to $71.4 million, which came in below Wall Street’s estimates of $75.6 million, according to Fiscal.ai data.

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 0.00% and -7.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates

Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are betting on a massive short squeeze as high short interest and institutional buying push prices toward major resistance levels.

Buzz is intensifying around potential acquisition interest from Big Pharma due to the company's unique, first-in-class oncology platform.

Traders are highlighting significant upcoming clinical milestones in NSCLC and other solid tumor indications that could dramatically boost valuation.

All eyes are on the upcoming Q2 earnings call for proof of strong commercial momentum and increased adoption of their lead therapy.

Feed

News

Sentiment

Earnings

Fundamentals

Info

IOVAIovance Biotherapeutics Inc

Fundamentals

Latest IOVA News